Plain-English translation of NCT06601296 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination approach for people with advanced kidney cancer whose disease has begun progressing despite prior immunotherapy treatment. The study combines three components: nivolumab (an immunotherapy drug you'll continue taking), targeted radiation therapy delivered in short, intense courses, and (a medication injected directly into one tumor to stimulate your immune system). The goal is to see whether this multi-pronged approach can control cancer growth better than current treatments alone.
Some people with advanced kidney cancer see their disease start growing again even while taking immunotherapy drugs. This trial exists to test whether combining this medication with radiation and an immune-stimulating injection might help overcome that resistance and give patients more treatment options.
You likely qualify if…
You likely don't qualify if…
You will continue your current immunotherapy drug (nivolumab) as a monthly infusion. You will also receive radiation therapy in three separate sessions, spaced four weeks apart, targeting your growing tumors. One tumor will receive three direct injections of the study medication over the course of several weeks. Throughout the trial, you'll have imaging scans and blood tests to monitor how your cancer responds. The study aims to enroll 15 patients over 3-4 years.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States